{"id":86659,"date":"2019-01-14T09:42:19","date_gmt":"2019-01-14T17:42:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/01\/unity-biotechnologies-selects-a-new-senolytic-candidate"},"modified":"2019-01-14T09:42:19","modified_gmt":"2019-01-14T17:42:19","slug":"unity-biotechnologies-selects-a-new-senolytic-candidate","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/01\/unity-biotechnologies-selects-a-new-senolytic-candidate","title":{"rendered":"UNITY Biotechnologies Selects a New Senolytic Candidate"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/unity-biotechnologies-selects-a-new-senolytic-candidate2.jpg\"><\/a><\/p>\n<p>Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop.<\/p>\n<p><strong>A new treatment for age-related diseases of the eye<\/strong><\/p>\n<p>Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with the goal of treating a range of <a href=\"http:\/\/ir.unitybiotechnology.com\/news-releases\/news-release-details\/unity-biotechnology-announces-completion-ubx1967-license-and\">age-related diseases of the eye<\/a>. This is the <a href=\"https:\/\/unitybiotechnology.com\/pipeline\/\">second drug<\/a> in the pipeline of this $677 million company. This drug is unique in the world of eye treatment; it targets and destroys <a href=\"https:\/\/www.leafscience.org\/aging-cellular-senescence\/\">senescent cells<\/a>, making it a <a href=\"https:\/\/www.leafscience.org\/senolytics\/\">senolytic<\/a> that targets one of the root causes of aging to treat disease.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.leafscience.org\/unity-biotechnologies-selects-a-new-senolytic-candidate\/\">https:\/\/www.leafscience.org\/unity-biotechnologies-selects-a-...candidate\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop. A new treatment for age-related diseases of the eye Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with [\u2026]<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-86659","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/86659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=86659"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/86659\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=86659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=86659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=86659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}